
Opinion|Videos|April 3, 2025
Checkpoint Inhibitors for Treatment of NMIBC
Experts share their initial impressions of the available data on immunotherapies, including PD-L1 inhibitors durvalumab and sasanlimab, being evaluated in bacille Calmette-Guérin (BCG)–unresponsive patients with non–muscle-invasive bladder cancer (NMIBC).
Advertisement
Episodes in this series

Video content above is prompted by the following:
- In addition to recent approval, several immunotherapies such as PD-(L)-1 inhibitors (durvalumab and sasanlimab) are being evaluated in BCG-unresponsive patients. What are your initial impressions of available data with immunotherapies?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Diet and Prostate Cancer, with Stephen J. Freedland, MD
2
67Cu-SAR-bisPSMA continues to show promise in mCRPC
3
How menstrual cycles influence bladder and pelvic floor symptoms
4
RCMIGI trial supports feasibility of reduced margins in image-guided prostate radiotherapy
5




















